Get started
Author

Stefan Norin

Observed names: Norin, Stefan, S Norin, S. Norin
ORCID: 0000-0002-7056-9900
Observed ORCID: 0000-0002-7056-9900
OpenAlex ID: A5023386496
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
2016 · M. Winqvist, A. Asklid, et al. · Haematologica · 121
PDF
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia
2011 · R. Gunnarsson, L. Mansouri, et al. · Haematologica · 108
PDF
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
2012 · Amir Hossein Daneshmanesh, Anna Porwit, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 84
Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients
2009 · R Gunnarsson, A Isaksson, et al. · Leukemia · 84
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
2018 · Maria Winqvist, Per-Ola Andersson, et al. · Haematologica · 63
PDF
Posttransplant Lymphoma A Single-Center Experience of 500 Liver Transplantations
2004 · Stefan Norin, Eva Kimby, et al. · Medical Oncology · 53
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia
2015 · C. Moreno, M. Montillo, et al. · Haematologica · 40
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation
2006 · C Karlsson, S Norin, et al. · Leukemia · 38
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
2018 · Sandra Eketorp Sylvan, Anna Asklid, et al. · Haematologica · 37
PDF
Up-regulated estrogen receptor β2 in chronic lymphocytic leukemia
2011 · Konstantin Yakimchuk, Stefan Norin, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 29
ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety
2020 · Enrique M. Ocio, Yvonne A. Efebera, et al. · Blood · 16
Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia
2009 · Stefan Norin, Eva Kimby, et al. · Medical Oncology · 15
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
2023 · Luděk Pour, Monika Szarejko, et al. · Haematologica · 14
PDF
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
2023 · Pieter Sonneveld, Paul G. Richardson, et al. · Clinical Lymphoma Myeloma & Leukemia · 13
PDF
ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)
2019 · Enrique M. Ocio, Yvonne A. Efebera, et al. · Blood · 13
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study
2023 · Enrique M. Ocio, Yvonne A. Efebera, et al. · Haematologica · 12
PDF
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region
2013 · Sandra Eketorp Sylvan, Lotta Hansson, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 11
Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study
2015 · Sandra Eketorp Sylvan, Henriette Skribek, et al. · Experimental Hematology · 9
Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program
2015 · Lotta Hansson, Maria Winqvist, et al. · Blood · 8
Determination of the recommended phase II dose of birinapant in combination with pembrolizumab: Results from the dose-escalation phase of BPT-201.
2019 · Russell J. Schilder, Mark Albertella, et al. · Journal of Clinical Oncology · 7
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy‐induced immunosuppression
2012 · Sandra Eketorp Sylvan, Eva Rossmann, et al. · British Journal of Haematology · 7
ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)—Optimal dose, updated efficacy and safety results.
2021 · Roman Hajek, Luděk Pour, et al. · Journal of Clinical Oncology · 6
A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study
2013 · Carol Moreno, Marco Montillo, et al. · Blood · 6
BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function
2026 · Ludek Pour, Sosana Delimpasi, et al. · Clinical Lymphoma Myeloma & Leukemia · 5
PDF
PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma
2024 · Ludek Pour, Ilina Micheva, et al. · Clinical Lymphoma Myeloma & Leukemia · 5
PDF
Works count: 71
Citation count: 847
H-index: 13
I10-index: 17
Year
Topic
Type